TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $30 from $24 and keeps a Buy rating on the shares. The firm said Q4 Filspari results were in line with the preannouncement with impressive 40% quarter-over-quarter sales growth and a 37% quarter-over quarter increase in PSFs. Filspari growth in IgAN should continue in 2025 as there are multiple tailwinds and the FSGS sNDA submission should occur by the end of Q1 setting up a potential approval by year-end.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Posts Strong 2024 Financial Results
- Strong Growth Potential and Strategic Advancements Drive Buy Rating for Travere Therapeutics
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- Is TVTX a Buy, Before Earnings?
- Travere Therapeutics price target raised to $47 from $45 at Guggenheim